Takimoto, C H <br/><br/>
Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Feb 2000 
 - 659-67 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article 
<br/><br/><label>ISSN: </label>0732-183X 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2000.18.3.659  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Agents, Phytogenic--administration & dosage<br/>Camptothecin--administration & dosage<br/>Drug Administration Schedule<br/>Female<br/>Follow-Up Studies<br/>Hematologic Diseases--chemically induced<br/>Humans<br/>Infusions, Intravenous<br/>Irinotecan<br/>Male<br/>Middle Aged<br/>Nausea--chemically induced<br/>Neoplasms--blood<br/>Vomiting--chemically induced